Emergent BioSolutions Inc. (EBS)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch EBS
See up to 3 months of EBS. The 7-day demo opens the 1M and 3M ranges and puts EBS on your watchlist.
Start 7-day demoLatest EBS insider trades
Donald W. Degolyer - DirectorOpen-market sale$126K- Paul Anthony Williams - OfficerOpen-market sale$20K
About Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. files with the SEC under CIK 0001367644 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
EBS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 20,800 | $146K |
EBS insider transactions (Form 4)
3658 Form 4 filings on record, the earliest from Oct 17, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Richard S. Lindahl - Officer | Tax withholding / forfeiture | Common Stock | 23,650 footnote F1 | $8.44 | $200K | |
| Richard S. Lindahl - Officer | Grant or award | Employee Stock Option (Right to buy) | 72,856 | $0.00 | - | |
| ||||||
 Coleen Glessner - Officer | Tax withholding / forfeiture | Common Stock | 8,199 footnote F1 | $8.44 | $69K | |
| Coleen Glessner - Officer | Grant or award | Employee Stock Option (Right to buy) | 44,834 | $0.00 | - | |
| ||||||
| Paul Anthony Williams - Officer | Tax withholding / forfeiture | Common Stock | 116 footnote F1 | $8.15 | $945 | |
| ||||||
| Richard S. Lindahl - Officer | Tax withholding / forfeiture | Common Stock | 683 footnote F1 | $8.15 | $6K | |
| ||||||
| Coleen Glessner - Officer | Tax withholding / forfeiture | Common Stock | 313 footnote F1 | $8.15 | $3K | |
| ||||||
| Jessica Perl - Officer | Tax withholding / forfeiture | Common Stock | 918 footnote F1 | $11.03 | $10K | |
| ||||||
| Coleen Glessner - Officer | Derivative | Common Stock | 28,847 footnote F1 | $10.92 | $315K | |
| Coleen Glessner - Officer | Tax withholding / forfeiture | Common Stock | 2,852 footnote F2 | $10.92 | $31K | |
| ||||||
| Paul Anthony Williams - Officer | Derivative | Common Stock | 8,655 footnote F1 | $10.92 | $95K | |
| Paul Anthony Williams - Officer | Tax withholding / forfeiture | Common Stock | 1,022 footnote F2 | $10.92 | $11K | |
| ||||||
 William Hartzel - Officer | Derivative | Common Stock | 5,771 footnote F1 | $10.92 | $63K | |
| William Hartzel - Officer | Tax withholding / forfeiture | Common Stock | 630 footnote F2 | $10.92 | $7K | |
| ||||||
| Richard S. Lindahl - Officer | Derivative | Common Stock | 46,155 footnote F1 | $10.92 | $504K | |
| Richard S. Lindahl - Officer | Tax withholding / forfeiture | Common Stock | 5,642 footnote F2 | $10.92 | $62K | |
| ||||||
| Simon C. Lowry - Officer | Tax withholding / forfeiture | Common Stock | 3,543 footnote F1 | $11.41 | $40K | |
| ||||||
| William Hartzel - Officer | Tax withholding / forfeiture | Common Stock | 610 footnote F1 | $10.88 | $7K | |
| ||||||
| Donald W. Degolyer - Director | Open-market sale | Common Stock | 17,801 footnote F1 | $10.54 footnote F2 | $188K | |
| ||||||
| Sujata Tyagi Dayal - Director | Open-market sale | Common Stock | 8,552 footnote F1 | $10.00 footnote F2 | $86K | |
| ||||||
| Richard S. Lindahl - Officer | Tax withholding / forfeiture | Common Stock | 4,995 footnote F1 | $9.60 | $48K | |
| ||||||
| Coleen Glessner - Officer | Open-market sale | Common Stock | 30,608 footnote F1 | $10.00 footnote F2 | $306K | |
| ||||||
| Kathryn C. Zoon - Director | Open-market sale | Common Stock | 7,086 | $8.87 | $63K | |
| Donald W. Degolyer - Director | Open-market sale | Common Stock | 7,844 | $8.65 | $68K | |
| William Hartzel - Officer | Tax withholding / forfeiture | Common Stock | 4,263 | $7.36 | $31K | |
| Richard S. Lindahl - Officer | Tax withholding / forfeiture | Common Stock | 2,733 | $6.63 | $18K | |
 Joseph C. Papa - Officer | Open-market purchase | Common Stock | 60,000 | $5.83 | $350K | |
 Louis W. Sullivan - Director | Grant or award | Common Stock | 34,403 | $0.00 | - | |
| Louis W. Sullivan - Director | Grant or award | Stock Option (Right to Buy) | 15,824 | $0.00 | - | |
| Simon C. Lowry - Officer | Grant or award | Common Stock | 29,482 | $0.00 | - | |
| Simon C. Lowry - Officer | Grant or award | Employee Stock Option (Right to buy) | 40,499 | $0.00 | - | |
| Coleen Glessner - Officer | Tax withholding / forfeiture | Common Stock | 18,674 | $9.01 | $168K | |
| Donald W. Degolyer - Director | Open-market sale | Common Stock | 25,000 | $10.91 | $273K | |
| Marvin L. White - Director | Open-market sale | Common Stock | 14,287 | $11.97 | $171K | |
| William Hartzel - Officer | Tax withholding / forfeiture | Common Stock | 632 | $11.97 | $8K | |
| Richard S. Lindahl - Officer | Grant or award | Common Stock | 15,000 | $0.00 | - | |
Item 7.01, 9.01
Item 8.01, 9.01
Item 2.02, 2.05, 5.02, 7.01, 9.01
Item 1.01, 7.01, 9.01
Recent EBS Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| DONALD DEGOLYER | Director | 17,800 | $126K | View on EDGAR | |
| PAUL WILLIAMS | Officer | 3,000 |
EBS insider trading FAQ
What is the latest insider trade for EBS?
Emergent BioSolutions Inc. (EBS) had 2 insider filings in the last 90 days, with the most recent on 2026-10-07. The full record for EBS runs to 58 Form 4 filings, the earliest from 2024-10-17. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying EBS stock?
No insider purchases of EBS were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling EBS stock?
2 insider sales of EBS were filed in the last 90 days, totaling $146K.
Where can I see EBS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects EBS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Donald W. Degolyer view on EDGAR
- - Paul Anthony Williams view on EDGAR
- - Paul Anthony Williams view on EDGAR
- - Paul Anthony Williams view on EDGAR
- - Richard S. Lindahl view on EDGAR
- - Coleen Glessner view on EDGAR
- - William Hartzel view on EDGAR
- - Sujata Tyagi Dayal view on EDGAR
- - Donald W. Degolyer view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where EBS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow EBS with a 7-day demo
- EBS on your watchlist
- Every EBS Form 4 filing on record
- Up to 3 months of EBS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
